Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy
Open Access
- 14 August 2024
- journal article
- review article
- Published by MDPI AG in Bioengineering
- Vol. 11 (8) , 830
Abstract
Among breast cancers, triple-negative breast cancer (TNBC) has been recognized as the most aggressive type with a poor prognosis and low survival rate. Targeted therapy for TNBC is challenging because it lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy, radiation therapy, and surgery are the common therapies for TNBC. Although TNBC is prone to chemotherapy, drug resistance and recurrence are commonly associated with treatment failure. Combination therapy approaches using chemotherapy, mAbs, ADC, and antibody–siRNA conjugates may be effective in TNBC. Recent advances with siRNA-based therapy approaches are promising for TNBC therapy with better prognosis and reduced mortality. This review discusses advances in nanomaterial- and nanobiomaterial-based siRNA delivery platforms for TNBC therapy exploring targeted therapy approaches for major genes, proteins, and TFs upregulated in TNBC tumors, which engage in molecular pathways associated with low TNBC prognosis. Bioengineered siRNA drugs targeting one or several genes simultaneously can downregulate desired genes, significantly reducing disease progression.Keywords
This publication has 158 references indexed in Scilit:
- Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple‐Negative Breast CancerAdvanced Therapeutics, 2024
- Multiple suppressing small interfering RNA for cancer treatment—Application to triple‐negative breast cancerBiotechnology Journal, 2023
- Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer TreatmentAdvanced Healthcare Materials, 2021
- Biodegradable Inorganic Nanostructured Biomaterials for Drug DeliveryAdvanced Materials Interfaces, 2020
- Protein‐Based Artificial Nanosystems in Cancer TherapySmall, 2020
- Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast CancerJAMA Oncology, 2018
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast CancerJAMA Oncology, 2017
- Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cellsJournal of Biomedical Materials Research Part A, 2016
- Multistage Vectored siRNA Targeting Ataxia‐Telangiectasia Mutated for Breast Cancer TherapySmall, 2013
- Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor ModelJournal of Pharmaceutical Sciences, 2013